Full Press Release Details
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI)will report financial results for the three months ended March 31, 2026, after the close of the U.S. financial markets on Thursday, May 7, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.
Conference Call and Webcast Information
| What: | OmniAb conference call to discuss first quarter 2026 financial results and business updates | |
| Date: | Thursday, May 7, 2026 | |
| Time: | 4:30 p.m. Eastern time (1:30 p.m. Pacific time) | |
| Phone: | U.S. (833) 461-5787 | |
| International (585) 542-9983 | ||
| Conference ID is 563758100 | ||
| Webcast: | Live and replay webcast of the call with slides will be availablehere. |
What:
OmniAb conference call to discuss first quarter 2026 financial results and business updates
Date:
Thursday, May 7, 2026
Time:
4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Phone:
U.S. (833) 461-5787
International (585) 542-9983
Conference ID is 563758100
Webcast:
Live and replay webcast of the call with slides will be availablehere.
About OmniAb®
OmniAb licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is what we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B-cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.
For more information, please visitwww.omniab.com.